Your Reagent Warehouse for COVID-19 Vaccine Development
Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. The SARS-CoV-2 pandemic presents an extraordinary challenge to the lives and health of the global population, resulting in a total of over 200 million diagnosed cases and 4.9 million death (as of October 2021). It also significantly affected society, economics and the environment around the world and changed everyone's life.
As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans. To better track and inform the viral variants, the World Health Organization (WHO) characterized several variants as "Variants of Concern (VOCs) " and "Variants of Interest (VOIs) " based on the risk posed to global public health. Today, of hundreds of variants that evolved from the original wild-type virus, Delta (PANGO lineage B.1.617.2/AY) are dominantly circulating and shaping the trend, reported to be responsible for most of the cases worldwide.
Vaccination is the cornerstone to prevent and control the spread of infectious diseases. Despite the importance of mask-wearing and social distancing, immunization by vaccines remains the most cost-effective way to protect our health. For this reason, vaccine development and production are at the center of each nation's public health policy.
ACROBiosystems is a life science company that provides reagents for the global vaccine industry. Having mobilized forces to develop SARS-CoV-2 recombinant antigens since the pandemic and accumulated mature technology and experiences with the virus and vaccines, we supply 200+ products and customized services that cover all the dominant strains of SARS-CoV-2 and support vaccine development of all technological platforms.
>>> Download the poster about core research tools for COVID-19 vaccine R&D
During the special time of need, we will continue to track the epidemic and are determined to facilitate the trial and application of the vaccines.
An Overview of Different COVID-19 Vaccines
In more than a year after the virus outbreak, various scientific research units and vaccine companies have worked to successfully develop a variety of COVID-19 vaccines. The vaccines can be classified by different technological platforms into whole virus vaccines, subunit vaccines, viral vector vaccines and gene vaccines (Fig. 1). Currently, 7 vaccines have obtained the WHO's emergency use authorization to be used in massivevaccination on a global scale, and over 300 vaccines are under development in pre-clinical or clinical trial stage.
Regulation of COVID-19 Vaccines Development and Licensure
(1)Antigen Detection:
Whole virus/Protein based:SDS-PAGE, MS, ELISA;
Virus vectored/ Nucleic acid:Western Blot, ELISA, FACS;
(2)Affinity Detection:
Protein based:ELISA, SPR, BLI;
(3)Efficacy evaluation:
IgG titer detection:ELISA Neutralizing Ab titer detection cVNT, pVNT, sVNT.
(1)Efficacy evaluation
①In vivo efficacy evaluation:
★Humoral immunity:
ⅠMouse/Monkey IgG titer detection
ⅡNeutralizing Ab titer detection
★Cellular immunity:Elispot
(2)In vitro efficacy evaluation:
①Antigen Detection
(1)Efficacy evaluation
①In vivo efficacy evaluation:
★Humoral immunity:
ⅠHuman IgG titer detection
ⅡNeutralizing Ab titer detection
★Cellular immunity:Elispot
②In vitro efficacy evaluation:Antigen Detection
(2)Toxicity evaluation
①ADE/VED detection:IgG isotype titer mesurement
>>> Development and Licensure of Vaccines to Prevent COVID-19
Antigen Detection
- Super stable SARS-CoV-2 spike trimer
- RBD/S trimer antigen quantitative detection kit
- Variants specific antibodies
Super stable SARS-CoV-2 spike trimer
The ideal control for antigen detection:Super stable SARS-CoV-2 spike trimer
High trimer purity (>90%) verified by SDS-PAGE, SEC-MALS and Negative Stain Electron Microscopy (NS-EM).
Provide trimer mutants of all VOCs, VOIs and other dominant strains.
Suitable as control in antigen detection tests.
Product List
Assay data
The purity of SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) is more than 90% verified by SDS-PAGE under reducing (R) condition. The molecular weight was around 550-660 kDa confirmed by SEC-MALS. The particles are similar in size and appearance to SARS-CoV-2 trimers reported in published literature verified by negative stain electron micrography.
SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) shows highest signal-to-noise ratio as compared to other spike proteins constructs in antibody tests in convalescent serum
Antigen Bioactivity Characterization
- ACE2 and other host receptors
- Antigen-ACE2 interaction service
ACE2 and other host receptors
High quality dimeric receptor:ACE2 proteins
Available in multiple species: Human, Mouse, Cynomolgus, Rat, Paguma larvata
Available in biotinylated or unconjugated forms that suits different experimental needs
High purity and binding activity with spike proteins verified with ELISA/SPR/BLI
Product List
| Molecule | Cat. No. | Species | Tag | Host | Product Description | Preorder/Order |
|---|---|---|---|---|---|---|
| ACE2 | AC2-H5205 | Human | Mouse IgG Fc Tag | HEK293 | Human ACE2 / ACEH Protein, Mouse IgG1 Fc Tag (MALS verified) |
|
| ACE2 | AC2-H5257 | Human | Fc Tag | HEK293 | Human ACE2 / ACEH Protein, Fc Tag (MALS verified) |
|
| ACE2 | AC2-H52H8 | Human | His Tag | HEK293 | Human ACE2 / ACEH Protein, His Tag (MALS verified) |
|
| ACE2 | AC2-H82E6 | Human | His Tag & Avi Tag | HEK293 | Biotinylated Human ACE2 / ACEH Protein, His,Avitag™ (MALS verified) |
|
| ACE2 | AC2-H82E8 | Human | His Tag & Avi Tag | HEK293 | Biotinylated Monomeric Human ACE2 / ACEH Protein, His,Avitag™ (MALS verified) |
|
| ACE2 | AC2-H82F9 | Human | Fc Tag & Avi Tag | HEK293 | Biotinylated Human ACE2 / ACEH Protein, Fc,Avitag™ |
|
| ACE2 | AC2-HP2H3 | Human | His Tag | HEK293 | PE-Labeled Human ACE2 / ACEH Protein, His TagStar Staining |
|
| ACE2 | AC2-M5248 | Mouse | His Tag | HEK293 | Mouse ACE2 / ACEH Protein, His Tag (MALS verified) |
|
| ACE2 | AC2-R5246 | Rat | His Tag | HEK293 | Rat ACE2 / ACEH Protein, His Tag (MALS verified) |
|
| ACE2 | AC2-C52H7 | Cynomolgus | His Tag | HEK293 | Cynomolgus ACE2 / ACEH Protein, His Tag |
|
| ACE2 | AC2-P5248 | Paguma larvata | His Tag | HEK293 | Paguma larvata ACE2 / ACEH Protein, His Tag (SPR verified) |
|
| ACE2 | AC2-M52H3 | Mink | His Tag | HEK293 | Mink ACE2 / ACEH Protein, His Tag (MALS & SPR verified) |
|
Assay data
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H3) at 2 μg/mL (100 μL/well) can bind Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) with a linear range of 2-20 ng/mL (QC tested).
Human ACE2, Fc Tag (Cat. No. AC2-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind recombinant SARS-CoV-2 Spike vaccine with an affinity constant of 16.9 nM as determined in a SPR assay (Biacore T200).
Immune Persistence Research
- Total Antibody Titer Determination
- Neutralizing Antibody Titer Detection
- Spike protein pseudovirus
- Broad-spectrum anti-RBD neutralizing antibody
Total Antibody Titer Determination
In vivo antibody titer determination in preclinical & clinical trial:S trimer/RBD/S1 IgG Antibody Titer Detection Kit (indirect ELISA)
Stable reagents with high batch-to-batch consistency to ensure data reliability for measuring changes in antibody titers at different times after vaccination
Provide different kits suitable for serum antibody detection in different species (rats, monkeys, humans) to meet the needs of preclinical and clinical experiments
Provide VOCs mutant-specific IgG antibody titer kits for antibody titer evaluation of vaccines against multiple viral variants
Assay data
Post-vaccination serum samples are tested with Anti-SARS-CoV-2 Antibody IgG Titer Serologic Assay Kit (Spike RBD) (Cat. No.RAS-T024), which accurately and precisely measure antibody titer in serum (Accuracy≤±15%; Intra-assay precision<10%; Inter-assay precision <15%).
Anti-SARS-CoV-2 Antibody IgG Quantitative Detection Kit (Spike Trimer) (Cat. No. RAS-T048) is developed for quantitative detection of IgG antibodies in post-vaccination serum. This kit is an important supplement to the existing vaccine evaluation methods which significantly improve the efficiency and accuracy of vaccine evaluation.
Toxicity Studies (antibody subtype detection)
-
antibody subtype detection
IgG Antibody Subtype Detection Kit (indirect ELISA):support research in ADE and ERD
High specificity that ensures antibodies are correctly typed
High stability and batch-to-batch consistency
The complete set of reagents needed for an experiment is provided in one kit to ease operation
Can test 90 + samples at the same time within 2h
Assay data
Cross-validation data for antibody subtype detection
- Background
- An Overview of Different COVID-19 Vaccines
- Regulation of COVID-19 Vaccines Development and Licensure
- Antigen Detection
- Antigen Bioactivity Characterization
- Immune Persistence Research
- Toxicity Studies (antibody subtype detection)